Journal of Pediatric Sciences

Sjogren Larsson Syndrome in three siblings of

an Indian family

Akanksha Gupta, Gunjan Mishra, Anubha Jain, Chandra Kanta

Journal of Pediatric Sciences 2015;7:e227

How to cite this article:

Gupta A, Mishra G, Jain A, Kanta C. Sjogren Larsson syndrome in three siblings of an Indian family. Journal of Pediatric Sciences. 2015;7:e227 DOI: <u>http://dx.doi.org/10.17334/jps.15884</u>

ORIGINAL ARTICLE

Sjogren Larsson Syndrome in three siblings of an Indian family

Akanksha Gupta, Gunjan Mishra, Anubha Jain, Chandra Kanta

Department of Pediatrics, King George's Medical University, Lucknow, Uttar Prdesh, India.

Abstract:

Sjogren Larsson Syndrome (SLS) is an uncommon autosomal recessive disorder characterized by intellectual disability, congenital icthyosis and spastic diplegia. Here we report three siblings with SLS from an Indian family with no history of consanguinity. One sibling had unusual features of spasticity and tremors in upper limbs.

Keywords: Sjogren-Larsson syndrome, icthyosis, quadriplegia, tremors **Submitted:** 01.07.2014 **Accepted:** 08.12.2014

Corresponding author: Dr Chandra Kanta, Associate Professor, Department of Pediatrics, KG Medical University, Lucknow, Uttar Prdesh, India, Phone: 0522 2257243 E mail: dr_chandrakanta@yahoo.co.in

Introduction

Sjogren Larsson Syndrome (SLS) is an autosomal recessive neurocutaneous disorder characterized by mental retardation, congenital icthyosis and occasionally spastic paraplegia and quadriplegia[1]. It is caused by mutations in dehydrogenase aldehyde 3A2 isoform 2 (ALDH3A2) which encodes fatty aldehyde dehydrogenase (FALDH)[2].Its deficiency leads to accumulation of long-chain fatty alcohols with structural consequences for cell membrane integrity which disrupt the barrier function of skin and the white matter of the brain. SLS occurs in all races and its prevalence has been estimated as

0.4 per 100,000 or lower[3].There have been only few case reports from India [4,5]

Case Reports:

We report a one and half year old male child presented with complaints of icthyotic skin changes, delayed developmental since birth, increased tone in all limbs and abnormal movements for one month. The child was a child of non consanguineous parent, and has no history suggestive of any perinatal insult. Laboratury examination revealed as anemia, icthyotic skin changes mainly over all the four limbs and trunk and spasticity quadriplegia. Muscle tone was increased more in the both upper limbs in comparison to lower limbs. Abnormal movements in the form of tremors were present in upper limbs. His development quotient was 25-30% and social quotient was 40-45%.Cardiovascular and respiratory system were normal. No facial dysmorphism or organomegaly was present (Figure 1).



Figure 1. Increased tone in upper limbs along with icthyotic skin changes in one and half year old male sibling.



Figure 2. Icthyotic skin changes in 13 years old female sibling.

Laboratory examinations revealed an anemia with hemoglobin 4.2 g/dl (anisocytosis, poicylocytosis, and hypochromia) and total leukocyte count- $4000/\text{mm}^3$, platelet count $480.000/\text{ mm}^3$. Serum B₁₂ and folate levels were

within the normal limits. Chest X Ray was normal. Fundus examination and electroencephalogram were found to be normal. Magnetic resonance imaging (MRI) showed hyperintense signal in peri and supraventricular white matter especially near bifrontal horn on T2 weighted and flair images, mild ventricular enlargement and restriction in diffusion weighted images in peri and supraventricular region. A Sharp lipid peak at TE 35 with mild decrease in NAA peak on 144 TE was found on magnetic resonance spectroscopy (MRS).






Figure 3. T2W Axial and FLAIR image showing hyperintense signal in peri and supraventricular white matter especially near bifrontal horn.




Figure 4. Restriction in Diffusion weighted imaging in periventricular and supraventricular region.




Figure 5. MRS showing sharp lipid peak at TE35 with mild decrease in NAA Peak on 144 TE.

Based on clinical picture, MRI and MRS findings diagnosis of Sjogren Larsson Syndrome

was made. The child was transfused packed red blood cells and iron, folate and multivitamins supplementation was given. Propanolol and baclofen were started for tremors and spasticity respectively. Fat restricted diet was advised and attendants were trained for physiotherapy. With treatment general condition improved and tremors subsided.

Two female siblings of child aged 6 and 13 years also had features of SLS. Both had intellectual disability, icthyosis involving limbs, trunk and neck and spastic paraparesis (Figure 2). They had skin changes and global developmental delay since birth. Both female siblings could not be investigated because of financial problems. Parents did not have any other normal child in the family.

Discussion

Sjögren-Larsson Syndrome (SLS), is an uncommon neurocutaneous disorder that exhibits recessive inheritance. autosomal It is characterized by intellectual disability. congenital ichthyosis and spastic diplegia or quadriplegia [1]. Though a high prevalence of SLS has been observed in north east of Sweden, it is rare in other parts of world and only few cases have been reported from India till now. [4,5]

SLS is caused by mutations in the ALDH3A2 gene that encodes fatty aldehyde dehydrogenase (FALDH). More than 70 mutations in ALDH3A2 have been discovered in SLS patients including amino acid substitutions, deletions, insertions, and splicing errors [2]. FALDH catalyses the oxidation of long chain aldehyde to acids and its deficiency leads fatty to accumulation of aldehyde-modified lipids or fatty alcohol in the skin and in the myelin [6]. There is also evidence of defective leukotriene B4 (LTB4) degradation caused by FALDH deficiency in patients with SLS.[7,8]

There is usually spastic diplegia, occasionally tetraplegia, with intellectual disability, epilepsy, and speech defects, dental, dermatological, skeletal, and retinal changes [4]. In quadriplegic patients also lower limbs are predominantly involved. In reported youngest sibling tone was increased more in upper limbs as compared to lower limbs. Other two female siblings had predominantly lower legs involvement. We also observed tremors in upper limbs in youngest sibling which have not been reported previously in SLS patients. Skin changes in SLS are in form of icthyosis which is generalized а hyperkeratosis of the trunk, joints, and the dorsal aspects of the hands and the feet. Most patients have erythema at birth with worsening of cutaneous symptoms during the first year of life. Pruritus is a prominent feature that is not found in other types of ichthyotic skin disorders [6]. Neurologic symptoms and signs appear during the first year or two of life. Approximately onehalf of the patients are non-ambulatory and most others require braces or crutches to walk [3]. A distinctive ophthalmologic finding is the presence of retinal crystalline inclusions, socalled glistening white dots, surrounding the fovea [9,10]. Although all SLS patients do not have the retinal inclusions, their presence is a pathognomonic feature for this neurocutaneous disease. Photophobia and myopia are also often present. Our patients presented with classical including icthyosis features and spastic quadriplegia but no ophthalmological findings.

MRI shows periventricular lesions, high intensity on T2-weighted and low intensity on T1weighted images at trigones of the lateral ventricles. Corpus callosum were involved. No atrophy or circumscribed lesions were seen on MRI. 1H-MRS of these lesions revealed high lipid and low N-acetyl aspartate peaks. MR imaging and proton MR spectroscopy of gray matter were normal [11,12,13]. The skin biopsy in SLS patients shows hyperkeratosis, focal parakeratosis, acanthosis, papillomatosis, and sparse dermal lymphocytic inflammatory infiltrate [5]. Genetic study and enzyme analysis could not be done due to financial constraints.

Treatment is mainly supportive. Oral acitretin therapy and dietary intervention a low-fat diet supplemented with medium-chain fatty acids is currently being evaluated in controlled trials for efficacy in improving neurologic and dermatologic symptoms. Improvement has been reported anecdotally[14,15] Topical medications, such as calcipotriene ointment, urea cream, and mineral oils, as well as frequent bathing or showering, have limited efficacy for patients with SLS. Favorable results have been reported with the use of zileuton, which inhibits LTB4 synthesis [16]. Physical therapy is important to counteract spasticity and preserve mobility for as long as possible [15,17].

So, skin examination should be done in all children presenting with developmental delay and/ or epilepsy and presence of icthyosis should prompt the diagnosis of Sjogren Larsson Syndrome.

References

- Sjögren T, Larsson T. Oligophrenia in combination with congenital ichthyosis and spastic disorders. Acta Psychiatr Scand. 1957; 32: 1–108.
- 2- Rizzo WB. Sjogren-Larsson syndrome: Molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Mol Genet Metab. 2007;90:1–9
- 3- Jagell Heijbel Sjögren-Larsson S, J. syndrome: physical and neurological patients. features. survey of 35 А Helv.Paediatr.Acta. 1982;37:519-530
- 4- Dhanuka AK, Gupta M. Sjogren Larsson Syndrome: a case report. Neurology India .2002;50:3:371-2.

- 5- Singh AR. Genetics of Sjögren Larsson Syndrome and a Case Report from India. Int J Hum Genet 2002; 2(4): 223-232.
- 6- Willemsen MA, Ijlst L, Steijlen PM, Rotteveel JJ, de Jong JG, van Domburg PH, et al. Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjogren- Larsson syndrome. Brain. 2001;124:1426–37.
- 7- Rizzo WB, Heinz E, Simon M, Craft DA. Microsomal fatty aldehyde dehydrogenase catalyzes the oxidation of aliphatic aldehyde derived from ether glycerolipid catabolism: implications for Sjögren-Larsson syndrome. Biochim Biophys Acta. 2000;1535:1–9
- 8- Willemsen MA, de Jong JG, van Domburg PH, Rotteveel JJ, Wanders RJA, Mayatepek E. Defective inactivation of leukotriene B4 in patients with Sjögren-Larsson syndrome. J Pediatr. 2000;136:258-260.
- 9- Jagell S, Polland W, Sandgren O. Specific changes in the fundus typical for the Sjögren-Larsson syndrome. An ophthalmological study of 35 patients. Acta Ophthalmol.(Copenh) 1980;58:321–330.
- 10- Willemsen MA, Cruysberg JR, Rotteveel JJ, Aandekerk AL, van Domburg PH, Deutman AF. Juvenile macular dystrophy associated with deficient activity of fatty aldehyde dehydrogenase in Sjögren-Larsson syndrome. Am.J.Ophthalmol. 2000;130:782– 789.
- 11- Dutra LA, de Acquino CC, Barsottini OG. Sjogren-Larsson syndrome: Case report and review of neurologic abnormalities and icthyosis. Neurologist. 2009;15:332–4
- 12- Miyanomae Y, Ochi M, Yoshioka H, Takaya K, Kizaki Z, Inoue F et al. Cerebral MRI and spectroscopy in Sjögren-Larsson syndrome: case report. Neuroradiology. 1995;37:225–228.
- 13- Willemsen MA, Van Der GM, van der Knaap MS, Heerschap A, van Domburg PH, Gabreels FJ et al. MR imaging and proton MR spectroscopic studies in Sjögren-Larsson syndrome: characterization of the leukoencephalopathy. Am.J.Neuroradiol. 2004;25:649–657.
- 14- Zalewska A, Schwartz RA. Dermatologic Manifestations of Sjogren-Larsson Syndrome Medication 2011; http:// emedicine.medscape.com/article/1114823medication visited on 20/6/14

- 15- Taube B, Billeaud C, Labrèze C, Entressangles B, Fontan D, Taïeb A. Sjögren-Larsson syndrome: early diagnosis, dietary management and biochemical studies in two cases. Dermatology. 1999;198:340-345
- 16- Willemsen MA, Lutt MA, Steijlen PM, Rotteveel JJ, de Jong JG, van Domberg PH et al. Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome. Eur J Pediatr. 2001;160:711-717
- 17- Auada MP, Taube MB, Collares EF, Tanaka AM, Cintra ML. Sjögren-Larsson syndrome: biochemical defects and follow up in three cases. Eur J Dermatol. 2002;12:263-266